🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07586384
Recruiting Not applicable

Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial

NCT07586384 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital of Wenzhou Medical University
Phase
Not applicable
Started
2025-11-05
Last updated
2026-05-14

Condition(s) studied

Stomach NeoplasmsRobotic Surgical Procedures

Investigational drug(s) / intervention(s)

Single-Port Robotic Surgical SystemTraditional Laparoscopic Surgery

Single-Port Robotic Surgical System: An investigational robotic-assisted surgical platform designed for single-port access. In this study, the system is utilized to perform radical proximal gastrectomy. The core surgical procedures are conducted through a centralized access point to assess the intraoperative safety and short-term clinical outcomes of this robotic-assisted approach.

Traditional Laparoscopic Surgery: Standard multi-port laparoscopic radical proximal gastrectomy performed as a clinical control. This procedure follows conventional laparoscopic techniques involving multiple abdominal incisions for the placement of surgical instruments and camera to treat proximal gastric cancer.

Study summary

To evaluate the safety and efficacy of SP1000 and conventional laparoscopy in radical gastrectomy for proximal gastric cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 18 and 75 years inclusive. ECOG performance status ≤ 2. Histologically confirmed proximal gastric cancer or Siewert type II adenocarcinoma of the esophagogastric junction. Clinical stage cT1-T3, N0-N+, M0. Tumor maximum diameter ≤ 4 cm and esophageal invasion ≤ 2 cm. Candidates for radical proximal gastrectomy (PG) with feasibility of R0 resection and functional anastomosis. Assessed by a Multidisciplinary Team (MDT) as suitable for PG rather than total gastrectomy, with no requirement for neoadjuvant therapy. Radiographic evidence of localized disease (no distant metastasis to liver, lung, or peritoneum via enhanced CT or MRI). ASA physical status classification ≤ III. Adequate bone marrow, hepatic, renal, cardiac, and pulmonary function. Ability to understand and provide written informed consent. Willingness and ability to comply with the 12-month postoperative follow-up schedule. Exclusion Criteria: * Clinical stage T4 or presence of distant metastasis. Esophageal invasion exceeding 2 cm. History of previous major gastric surgery (e.g., partial or total gastrectomy). Other malignant tumors within the last 5 years. Severe organic diseases that preclude safe anesthesia or surgery (e.g., severe heart failure, pulmonary fibrosis). Requirement for emergency surgery due to active gastric bleeding, perforation, or acute obstruction. Pregnant or lactating women. Serious psychiatric disorders or cognitive impairment that interferes with study compliance. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang Recruiting

More First Affiliated Hospital of Wenzhou Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07586384 on ClinicalTrials.gov ↗ ← All trials in China